Gyrodyne , LLC (NASDAQ:GYRO) Short Interest Down 37.5% in March

Gyrodyne , LLC (NASDAQ:GYRO) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 45 shares, a decline of 37.5% from the February 26th total of 72 shares. Based on an average daily trading volume, of 798 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Trading of Gyrodyne

Several institutional investors and hedge funds have recently made changes to their positions in GYRO. Bulldog Investors LLP purchased a new stake in shares of Gyrodyne during the third quarter valued at $601,000. Teton Advisors LLC bought a new stake in Gyrodyne during the 3rd quarter valued at about $177,000. Susquehanna International Group LLP bought a new stake in Gyrodyne during the 3rd quarter valued at about $142,000. Finally, Advisory Services Network LLC purchased a new stake in Gyrodyne in the 3rd quarter valued at about $77,000. 71.36% of the stock is currently owned by institutional investors.

Gyrodyne Trading Down 2.3%

Shares of NASDAQ GYRO traded down $0.19 during midday trading on Friday, hitting $7.99. The company’s stock had a trading volume of 2,198 shares, compared to its average volume of 961. The business’s 50 day moving average is $8.69 and its two-hundred day moving average is $9.32. Gyrodyne has a 12-month low of $6.80 and a 12-month high of $12.00.

Gyrodyne Company Profile

Gyrodyne Company of America, Inc is a New York–based real estate investment and development firm specializing in medical office buildings and professional facilities. Listed on the NASDAQ under the ticker GYRO, the company’s principal business activity is the ownership, leasing and management of commercial properties tailored to healthcare and life sciences tenants. By focusing on outpatient diagnostic and treatment centers, clinical laboratories and related professional suites, Gyrodyne generates steady rental income and seeks to provide purpose-built environments that meet the specific needs of medical practitioners and research organizations.

The company’s core property portfolio is anchored by an approximately 87-acre campus situated in Stony Brook, Long Island.